- Home
- KIDS vs KROS Comparison
KIDS vs KROS Comparison
Compare KIDS & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIDS
- KROS
- Stock Information
- Founded
- KIDS 2007
- KROS 2015
- Country
- KIDS United States
- KROS United States
- Employees
- KIDS N/A
- KROS N/A
- Industry
- KIDS Medical/Dental Instruments
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- KIDS Health Care
- KROS Health Care
- Exchange
- KIDS Nasdaq
- KROS Nasdaq
- Market Cap
- KIDS 524.3M
- KROS 565.0M
- IPO Year
- KIDS 2017
- KROS 2020
- Fundamental
- Price
- KIDS $16.84
- KROS $15.22
- Analyst Decision
- KIDS Strong Buy
- KROS Buy
- Analyst Count
- KIDS 7
- KROS 14
- Target Price
- KIDS $24.86
- KROS $20.56
- AVG Volume (30 Days)
- KIDS 237.7K
- KROS 1.1M
- Earning Date
- KIDS 10-28-2025
- KROS 11-06-2025
- Dividend Yield
- KIDS N/A
- KROS N/A
- EPS Growth
- KIDS N/A
- KROS N/A
- EPS
- KIDS N/A
- KROS 0.47
- Revenue
- KIDS $227,410,000.00
- KROS $232,844,000.00
- Revenue This Year
- KIDS $17.32
- KROS $6,657.47
- Revenue Next Year
- KIDS $13.56
- KROS N/A
- P/E Ratio
- KIDS N/A
- KROS $32.70
- Revenue Growth
- KIDS 19.90
- KROS 85820.30
- 52 Week Low
- KIDS $15.28
- KROS $9.12
- 52 Week High
- KIDS $32.00
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- KIDS 40.48
- KROS 49.86
- Support Level
- KIDS $16.15
- KROS $14.77
- Resistance Level
- KIDS $18.85
- KROS $15.47
- Average True Range (ATR)
- KIDS 0.77
- KROS 0.69
- MACD
- KIDS -0.02
- KROS 0.01
- Stochastic Oscillator
- KIDS 25.56
- KROS 70.74
About KIDS OrthoPediatrics Corp.
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.